重新审视重复两阶段膝关节置换翻修术:结局、风险与决策
该研究分析114例初次治疗失败后接受重复两阶段翻修术的慢性膝关节假体周围感染患者,发现34.2%因再感染或持续感染未再植入,再植入者中44.0%因再感染再次翻修,总体再感染率39.5%、截肢12例、死亡率15.8%,初次、重复、再重复两阶段病例5年无感染生存率分别为93%、72%、43%。
要点
- 重复两阶段翻修术再感染率39.5%,包括12例截肢和15.8%死亡率。
- 初次、重复、再重复两阶段病例5年无感染生存率分别为93%、72%、43%。
- 高Charlson合并症指数、同一微生物复发、初次置换至再感染间隔短与未再植入相关。
核心结论
- 本研究强调初次两阶段翻修术治疗膝关节假体周围感染的有效性,并指出后续尝试的挑战和较低成功率。
- 作者强调识别高危患者以制定个体化治疗方案并设定现实结局预期的重要性。
研究设计与样本
- 回顾性分析2010年至2018年间因慢性膝关节假体周围感染接受重复两阶段翻修术的114例患者。
- 从初始1351例队列中排除231例(18例记录不完整或方案不依从,213例既往翻修),剩余1119例中150例发生再感染,排除36例未行重复两阶段翻修术后最终纳入114例。
- 结局采用基于德尔菲共识的成功标准评估:伤口愈合、无进一步感染干预、无假体周围感染相关死亡。
主要发现
- 34.2%的患者因再感染或持续感染未进行再植入,受高Charlson合并症指数评分、同一微生物复发、初次关节置换至再感染间隔较短等因素影响。
- 再植入患者中44.0%因再感染接受进一步翻修。
- 对1119例初次、75例重复和24例再重复两阶段病例的Kaplan-Meier分析显示,5年无感染生存率分别为93%、72%和43%。
- 本研究识别出同一微生物重复感染、持续性假体周围感染或多次间隔物翻修手术患者存在显著再感染风险。
- 本系列观察到39.5%的再感染率,包括12例截肢和15.8%的死亡率。
关键数值与推荐
- 基于德尔菲共识的成功标准:伤口愈合、无进一步感染干预、无假体周围感染相关死亡。
- 1119例初次两阶段病例5年无感染生存率为93%。
- 75例重复两阶段病例5年无感染生存率为72%。
- 24例再重复两阶段病例5年无感染生存率为43%。
- 再感染率39.5%,包括12例截肢,死亡率15.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据等级为III级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic periprosthetic joint infection (PJI) presents a major challenge in knee arthroplasty, with varying success rates reported for two-stage exchange arthroplasty (EA) and a lack of consensus on managing failures from such procedures. This study evaluated repeat two-stage EA outcomes for knee PJI after initial treatment failure to identify the risk factors for reimplantation unsuitability and reinfection. METHODS: We analyzed 114 patients who underwent repeat EA for chronic knee PJI between 2010 and 2018. From an initial cohort of 1,351 patients, we excluded 231: 18 for incomplete records or protocol non-compliance and 213 for prior revisions. Among the remaining 1,119 patients, 150 experienced reinfection. After excluding 36 who did not undergo repeat EA, the final cohort comprised 114 patients. Outcomes were evaluated using Delphi-based consensus success criteria as follows: healed wounds, no further infection interventions, and no PJI-related mortality. RESULTS: In our study, 34.2% of the patients did not proceed with reimplantation due to reinfection or ongoing infection, which was influenced by factors such as high Charlson Comorbidity Index scores, recurrence of a microorganism, and shorter intervals between initial arthroplasty and reinfection. Among the reimplanted patients, 44.0% underwent further revision for rereinfection. Kaplan-Meier analysis of 1,119 initial, 75 repeat, and 24 re-repeat two-stage cases revealed 5-year infection-free survival rates of 93, 72, and 43%, respectively. This study identified significant reinfection risks in patients who have repeated infections by the same microorganisms, persistent PJI, or multiple spacer redo procedures. A 39.5% rereinfection rate, including 12 amputations and a 15.8% mortality rate, was observed in this series. CONCLUSIONS: This study underscores the effectiveness of first-time two-stage EA for knee PJI and notes the challenges and lower success rates of subsequent attempts. This emphasizes the importance of identifying high-risk patients for tailored treatment plans and setting realistic expectations of outcomes. LEVEL OF EVIDENCE: III.
引用
- Huang YY, Hu CC, Lee SH, et al. Rethinking Repeat Two-Stage Knee Exchange Arthroplasty: Outcomes, Risks, and Decision-Making. J Arthroplasty. 2025. PMID: 39814115. doi:10.1016/j.arth.2025.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。